

# CITATION REPORT

List of articles citing

## Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis

DOI: 10.1001/jamacardio.2020.4511  
JAMA Cardiology, 2021, 6, 148-158.

**Source:** <https://exaly.com/paper-pdf/77812276/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
416	Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. <b>2020</b> , 142, 2205-2215		77
415	The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now. <b>2020</b> , 43, 1376-1387		7
414	Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations From VERTIS CV. <b>2021</b> , 143, 602-605		11
413	Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: The Heart and Kidney Working Better Together. <b>2021</b> , 143, 322-325		1
412	FIGARO-DKD adds new evidence to the cardiovascular benefits of finerenone across the spectrum of patients with type 2 diabetes and chronic kidney disease.. <b>2021</b> , 42, 4789-4790		2
411	Sex and ethnic differences in the cardiovascular complications of type 2 diabetes. <b>2021</b> , 12, 20420188211034297		
410	From Proteinuria to Fibrosis: An Update on Pathophysiology and Treatment Options. <b>2021</b> , 46, 411-420		2
409	The year in cardiovascular medicine 2020: epidemiology and prevention. <b>2021</b> , 42, 813-821		13
408	Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. <b>2021</b> ,		7
407	Diabetic Kidney Disease Represents a Locus of Opportunity. <b>2021</b> , 12, 650503		
406	Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. <b>2021</b> , 20, 75		3
405	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. <b>2021</b> , 44, 1159-1167		7
404	Glucose-Lowering Medications and Cardiovascular Outcomes. <b>2021</b> , 23, 24		0
403	Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis. <b>2021</b> , 23, 1672-1676		9
402	The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending. <b>2021</b> , 42, 1458-1459		2
401	Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes. <b>2021</b> , 44, 1236-1241		12
400	Slowing Progression in CKD: DAPA CKD and Beyond. <b>2021</b> , 16, 1117-1119		3

399	Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study. <b>2021</b> , 20, 59	5
398	Can biomarkers help find the 'sweet spot' for treating patients with diabetes?. <b>2021</b> , 23, 1037-1039	
397	Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Transplantation: What Are We Waiting For?. <b>2021</b> , 2, 1174-1178	4
396	Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes?. <b>2021</b> , 144, 4-6	9
395	Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. <b>2021</b> , 20, 83	5
394	Heart failure at the crossroads of cardiology and diabetology. <b>2021</b> , 175, 108844	
393	Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility. <b>2021</b> , 175, 108796	2
392	Hypertension in diabetes care: emerging roles of recent hypoglycemic agents. <b>2021</b> , 44, 897-905	2
391	The impact of diabetes on heart failure development: The cardio-renal-metabolic connection. <b>2021</b> , 175, 108831	0
390	Newer drug treatments for type 2 diabetes. <b>2021</b> , 373, n1171	2
389	SGLT2 inhibitors: Do we need other evidences?. <b>2021</b> , 87, 18-19	
388	Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear. <b>2021</b> , 40, 772-778	0
387	The current schemes of insulin therapy: Pro and contra. <b>2021</b> , 175, 108817	3
386	Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators. <b>2021</b> , 10,	1
385	Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade. <b>2021</b> , 26, 858-871	2
384	Kidney outcomes using a sustained ≥0% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials. <b>2021</b> , 44, 1139-1143	6
383	Sodium-glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria.. <b>2021</b> , 14, 2463-2471	3
382	The Johns Hopkins Ciccarone Center's expanded 'ABC's approach to highlight 2020 updates in cardiovascular disease prevention. <b>2021</b> , 6, 100181	

381	Sodium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?. <b>2021</b> , 23, 2194-2196	2
380	Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF. <b>2021</b> , 35, 1077-1078	
379	Nephropathie bei Diabetes. <b>2021</b> , 21, 31-35	
378	Les inhibiteurs de SGLT2 sont d'abord des antidiabétiques oraux !. <b>2021</b> , 15, 353-354	
377	Costs and healthcare utilisation of patients with chronic kidney disease in Spain. <b>2021</b> , 21, 536	4
376	Cardiovascular Outcome Trials with Glucose-Lowering Drugs. <b>2021</b> , 23, 75	3
375	The effects of antidiabetic agents on heart failure. <b>2021</b> , 1	0
374	Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?. <b>2021</b> , 36, 672-681	1
373	Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM. <b>2021</b> , 8, 690529	1
372	Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. <b>2021</b> ,	1
371	Emerging Targets in Type 2 Diabetes and Diabetic Complications. <b>2021</b> , 8, e2100275	13
370	Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. <b>2021</b> , 120, 154799	9
369	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. <b>2021</b> , 144, 74-84	9
368	Adipose Tissue-Endothelial Cell Interactions in Obesity-Induced Endothelial Dysfunction. <b>2021</b> , 8, 681581	5
367	Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus. <b>2021</b> , 1	1
366	Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?. <b>2021</b> , 81, 1365-1371	6
365	Heal Thyself: SGLT2 Inhibition Limits Regenerative Cell Exhaustion and Heals Damaged Vessels. <b>2021</b> , 70, 1620-1622	0
364	Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors. <b>2021</b> , 23, 1260-1275	12

363	CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS. <b>2021,</b>	5
362	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <b>2021,</b>	22
361	Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on first-line oral therapy for type 2 diabetes: A claims-based observational cohort study. <b>2021, 23, 2741-2751</b>	0
360	Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <b>2021, 385, 2252-2263</b>	103
359	Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. <b>2021, 385, 669-670</b>	
358	SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD. <b>2021, 162,</b>	1
357	Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study. <b>2021, 330, 8-13</b>	1
356	Cardiorenal Syndrome: An Important Subject in Nephrocardiology. <b>2021, 39, 455-469</b>	3
355	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. <b>2021, 174, 1065-1072</b>	6
354	SGLT2 inhibitors: the story continues to unfold. <b>2021,</b>	3
353	Canagliflozin and myocardial oxidative stress: SGLT1 inhibition takes centre stage. <b>2021,</b>	1
352	Klotho: A possible mechanism of action of SGLT2 inhibitors preventing episodes of acute kidney injury and cardiorenal complications of diabetes. <b>2021, 26, 1963-1971</b>	3
351	Recent Insights into the Nutritional Antioxidant Therapy in Prevention and Treatment of Diabetic Vascular Complications - A comprehensive Review. <b>2021,</b>	0
350	Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes. <b>2021, 23, 2614-2622</b>	0
349	A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease. <b>2021, 81, 1491-1511</b>	6
348	Sodium-Glucose Cotransporter 2 Inhibitors and the Kidney. <b>2021, 34, 225-234</b>	0
347	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <b>2021, 42, 3599-3726</b>	875
346	Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients With Type 2 Diabetes Mellitus. <b>2021,</b>	1

345	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. <b>2021</b> , 23, 1798-1799	4
344	Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial. <b>2022</b> , 24, 135-141	6
343	Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents. <b>2021</b> , 20, 175	1
342	A Comprehensive Cardiovascular-Renal-Metabolic Risk Reduction Approach to Patients with Type 2 Diabetes Mellitus. <b>2021</b> , 134, 1076-1084	0
341	Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <b>2021</b> , 10, e022222	2
340	Prevention of Diabetes Macrovascular Complications and Heart Failure. <b>2021</b> , 50, 415-430	2
339	2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes. <b>2021</b> , 1, 129-146	
338	Effects of SGLT2 Inhibitors beyond Glycemic Control-Focus on Myocardial SGLT1. <b>2021</b> , 22,	2
337	Possibilities of cardio- and nephroprotective effects of drugs of the SGLT2 inhibitor group. <b>2021</b> , 99, 172-176	
336	Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?. <b>2021</b> , 1	1
335	SGLT2-Inhibition reverts urinary peptide changes associated with severe COVID-19: An in-silico proof-of-principle of proteomics-based drug repurposing. <b>2021</b> , 21, e2100160	2
334	Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. <b>2021</b> ,	22
333	SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies. <b>2021</b> , 172, 105836	2
332	Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. <b>2021</b> , 123, 154838	10
331	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. <b>2021</b> , 9, 653-662	58
330	Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis. <b>2021</b> ,	7
329	Sodium-Glucose Cotransporter 2 Inhibitor Use Associated With Fournier's Gangrene: A Review of Case Reports and Spontaneous Post-Marketing Cases.. <b>2022</b> , 40, 78-86	1
328	Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. <b>2021</b> , 9,	0

327	Adding Sodium-Glucose Co-Transporter 2 Inhibitors to Sulfonylureas and Risk of Hypoglycemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <b>2021</b> , 12, 713192	
326	The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?. <b>2021</b> , 108008	1
325	Euglycemic diabetic ketoacidosis following major vascular surgery is a new item on the differential for postoperative acidosis. <b>2021</b> , 7, 778-780	1
324	Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease. <b>2021</b> , 20, 213	5
323	Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. <b>2021</b> , 10, CD013650	3
322	A novel hypothesis linking low-grade ketonaemia to cardio-renal benefits with sodium-glucose cotransporter-2 inhibitors. <b>2022</b> , 24, 3-11	1
321	Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. <b>2021</b> , 78, 1587-1598	3
320	SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials. <b>2021</b> ,	5
319	SGLT2 Inhibitors. <b>2021</b> , 155-166	
318	Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom. <b>2021</b> , 24, 289	1
317	The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review. <b>2021</b> , 12, 751214	2
316	Severe Hypoglycemia and Incident Heart Failure among Adults With Type 2 Diabetes. <b>2021</b> ,	2
315	The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. <b>2021</b> , 1	2
314	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. <b>2021</b> , 20, 218	7
313	The rise of SGLT2 inhibitors: the time is now for cardiovascular specialists to lead the charge. <b>2021</b> , 1-3	
312	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. <b>2021</b> ,	2
311	Interpreting Absolute and Relative Risk Reduction in the Context of Recent Cardiovascular Outcome Trials in Patients with Type 2 Diabetes. <b>2021</b> , 21, 45	0
310	Cardiovascular benefits of SGLT2 inhibitors in patients with heart failure: a meta-analysis of small and large randomized controlled trials. <b>2021</b> , 11, 262-272	1

309	Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity. <b>2021</b> , 11, 504-529	0
308	Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors.. <b>2021</b> , 2, 1203-1230	3
307	SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness. <b>2021</b> , 1	0
306	Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. <b>2021</b> ,	7
305	Hypertriglyceridemia-Induced Acute Pancreatitis, Euglycemic Diabetic Ketoacidosis and COVID-19 Infection in a Patient With Type 2 Diabetes Taking a Sodium-Glucose Cotransporter 2 Inhibitor. <b>2021</b> , 13, e19828	
304	SGLT-2 inhibitors as cardio-renal protective agents. <b>2021</b> , 127, 154937	4
303	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial. <b>2021</b> ,	10
302	Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors. <b>2021</b> ,	2
301	Cardiovascular benefit of SGLT2 inhibitors. <b>2021</b> , 1-14	
300	Dysglycemia and Incident Heart Failure among Blacks: The Jackson Heart Study. <b>2021</b> , 245, 1-1	2
299	Initiation of SGLT2 Inhibitors and the Risk of Lower Extremity Minor and Major Amputation in Patients with Type 2 Diabetes and Peripheral Arterial Disease: A Health Claims Data Analysis. <b>2021</b> ,	2
298	Diabetes Status Modifies the Association Between Different Measures of Obesity and Heart Failure Risk Among Older Adults: A Pooled Analysis of Community-Based NHLBI Cohorts. <b>2021</b> ,	1
297	Aging and Redox Pathways in Diabetes. <b>2022</b> , 349-368	1
296	Connexin 43: A Target for the Treatment of Inflammation in Secondary Complications of the Kidney and Eye in Diabetes.. <b>2022</b> , 23,	0
295	The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients.. <b>2022</b> ,	0
294	SGLT2-Inhibitoren: Schutz für die Nieren.	
293	100 Jahre Insulin: Das Hormon des Lebens.	
292	Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis.. <b>2021</b> , 100, e27802	



291	Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.. <b>2021</b> , e14780	1
290	SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis.. <b>2022</b> ,	4
289	Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers.. <b>2021</b> , 12, 786706	2
288	Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails. <b>2022</b> , 24, 553-564	
287	Glycemic Markers and Heart Failure Subtypes: The Multi-Ethnic Study of Atherosclerosis (MESA).. <b>2022</b> ,	3
286	Trends in the Incidence of Hospitalization for Major Diabetes-Related Complications in People With Type 1 and Type 2 Diabetes in Australia, 2010-2019.. <b>2022</b> ,	2
285	The year in cardiovascular medicine 2021: diabetes and metabolic disorders.. <b>2022</b> ,	2
284	Clinical Predictors and Long-term Impact of Acute Kidney Injury on Progression of Diabetic Kidney Disease in Chinese Patients with Type 2 Diabetes.. <b>2022</b> ,	0
283	Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.. <b>2022</b> ,	0
282	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.. <b>2022</b> , 24, 4-131	50
281	Patterns of Medication Use and Prescription Fills for Cardioprotective Anti-Hyperglycemic Agents in the United States.	0
280	Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.. <b>2022</b> , 22, 39	5
279	The role of inflammation as a preponderant risk factor in cardiovascular diseases.. <b>2022</b> ,	0
278	Sodium-glucosecotransporter 2 inhibitors in heart failure with reduced or preserved ejectionfraction: a meta-analysis.. <b>2022</b> ,	2
277	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. <b>2021</b> , 36, 108101	2
276	Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.. <b>2022</b> , 79, 432-444	2
275	Eligibility and Response to Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Therapy: How Useful Are Cardiac Biomarkers?. <b>2022</b> , 79, 445-447	
274	Angiotensin Receptor-Nepriylsin Inhibition in Acute Myocardial Infarction.. <b>2022</b> , 386, 603	

273	Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.. <b>2022,</b>	1
272	Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease.. <b>2022, 12,</b>	0
271	Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals.. <b>2022, 20, 63</b>	0
270	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. <b>2021,</b>	26
269	Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis.. <b>2021,</b>	2
268	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.. <b>2022, 45, S144-S174</b>	46
267	11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022.. <b>2022, 45, S175-S184</b>	15
266	The Use of SGLT-2 Inhibitors Coupled With a Strict Low-Carbohydrate Diet: A Set-Up for Inducing Severe Diabetic Ketoacidosis.. <b>2022, 15, 11795476221090045</b>	1
265	Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities.. <b>2022, 1</b>	0
264	Contemporary Medical Therapies for Patients with Peripheral Artery Disease and Concomitant Type 2 Diabetes Mellitus: a Review of Current Evidence.. <b>2022, 1</b>	0
263	Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention.. <b>2022, 22, 129</b>	1
262	Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.. <b>2022,</b>	
261	Clinical progress note: Indications for and management of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in hospitalized patients.. <b>2022, 17, 360-363</b>	1
260	SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure-A Concise Review.. <b>2022, 11,</b>	1
259	Preventing all-cause hospitalizations in type-2 diabetes with SGLT2 inhibitors and GLP-1 receptor agonists - narrative review and clinical approach.. <b>2022,</b>	0
258	Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.. <b>2022, 21, 47</b>	1
257	Implementation of Cardiometabolic Centers and Training Programs.. <b>2022, 1</b>	
256	Modern Approaches to Treatment of Chronic Heart Failure in Patients with Type 2 Diabetes Mellitus. <b>2022, 7, 14-31</b>	

255	Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.. <b>2022,</b>	0
254	Optimizing Foundational Therapies in Patients With HFrEF. <b>2022,</b>	6
253	Effects of an SGLT Inhibitor on the Production, Toxicity, and Elimination of Gut-Derived Uremic Toxins: A Call for Additional Evidence.. <b>2022,</b> 14,	1
252	Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.. <b>2022,</b> 1	1
251	Risk of outcomes in a Spanish population with chronic kidney disease.	
250	The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.. <b>2022,</b>	1
249	Advances in computer-aided drug design for type 2 diabetes.. <b>2022,</b> 1-12	
248	Canagliflozin and Dapagliflozin Attenuate Glucolipototoxicity-Induced Oxidative Stress and Apoptosis in Cardiomyocytes via Inhibition of Sodium-Glucose Cotransporter-1.. <b>2022,</b> 5, 216-225	1
247	JAMA Cardiology-The Year in Review, 2021.. <i>JAMA Cardiology,</i> <b>2022,</b>	16.2
246	New Diabetic Medication Sodium-Glucose Cotransporter-2 Inhibitors Can Induce Euglycemic Ketoacidosis and Mimic Surgical Diseases: A Case Report and Review of Literature.. <b>2022,</b> 9, 828649	0
245	Potential Use of SGLT-2 Inhibitors in Obstructive Sleep Apnea: A new treatment on the horizon.. <b>2022,</b> 1	0
244	Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes.. <b>2022,</b> 1	
243	Cardiometabolic-based chronic disease: adiposity and dysglycemia drivers of heart failure.. <b>2022,</b> 1	0
242	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <b>2022,</b> 101161CIR0000000000001063	35
241	Glycated Hemoglobin as an Integrator of Cardiovascular Risk in Individuals Without Diabetes: Lessons from Recent Epidemiologic Studies.. <b>2022,</b> 1	2
240	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <b>2022,</b>	49
239	Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus.. <b>2022,</b>	0
238	Low glucose metabolizing capacity and not insulin resistance is primary etiology of type 2 Diabetes Mellitus: A hypothesis. <b>2022,</b> 162, 110804	

237	Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes - Data from a randomized, placebo-controlled study.. <b>2022</b> , 16, 101175	0
236	Diabetes in Kidney Transplantation.. <b>2021</b> , 28, 596-605	0
235	Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure?. <b>2021</b> ,	
234	2021 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk. <b>2021</b> , 22, 259-267	1
233	Can chronic kidney disease lead to chronic heart failure, and does worsening chronic heart failure lead to chronic kidney disease progression.. <b>2021</b> , 31,	0
232	Can we cure diabetic kidney disease? Present and future perspectives from a nephrologist's point of view.. <b>2021</b> ,	3
231	SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs.. <b>2021</b> , 20, 236	8
230	2021 Korean Diabetes Association Clinical Practice Guidelines for Diabetes: Diabetic Kidney Disease. <b>2021</b> , 22, 268-273	1
229	Coronary Artery Disease in Chronic Kidney Disease: Need for a Heart-Kidney Team-Based Approach.. <b>2021</b> , 16, e48	0
228	Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?. <b>2022</b> , 13, 20420188221090001	1
227	Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis.	
226	Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.. <b>2022</b> , 22, 213	1
225	Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations.. <b>2022</b> ,	0
224	Diabetes Medications and Cardiovascular Disease Prevention. <b>2022</b> , 12, 61-71	
223	Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.. <b>2022</b> , 17, e0267025	0
222	Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers.. <b>2022</b> , 13, 786767	0
221	Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <b>2022</b> ,	1
220	SGLT2 inhibition attenuates arterial dysfunction and decreases vascular F-actin content and expression of proteins associated with oxidative stress in aged mice.. <b>2022</b> , 1	2

219	Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials.. <b>2022,</b>	8
218	Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials. <b>2021,</b> 18, 783-795	2
217	Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER.. <b>2022,</b> 22, 111	0
216	Prognostic significance of hypertriglyceridemia in patients at high and very high cardiovascular risk depending on the concentration of high-sensitivity C-reactive protein.. <b>2022,</b>	
215	Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes.. <b>2022,</b> 36, 108204	0
214	20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units. <b>2022,</b> 9, 149	1
213	Novel Markers in Diabetic Kidney DiseaseCurrent State and Perspectives. <b>2022,</b> 12, 1205	0
212	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.. <b>2022,</b>	1
211	Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease.. <b>2022,</b> 117, 924-935	2
210	Quantification and treatment of congestion in heart failure: A clinical and pathophysiological overview. <b>2022,</b>	
209	Relationship of diabetes, heart failure, and N-terminal pro-B-type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation.. <b>2022,</b>	0
208	Chronic Kidney Disease Is a Risk Enhancer for Cardiovascular Diseases. <b>2022,</b> 271-306	
207	SGLT2 Inhibitors and Peripheral Vascular Events. <b>2022,</b>	0
206	Impact of SodiumGlucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular AgingWhat Do We Know So Far? (A Narrative Review). <b>2022,</b> 12, 803	3
205	Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes.	1
204	Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes.	0
203	Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With SodiumGlucose Cotransporter-2 Inhibitors Versus Metformin.	1
202	Gliflozins in the Management of Cardiovascular Disease. <b>2022,</b> 386, 2024-2034	6

201	Validation of the WATCH-DM and TRS-HF DM Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis.	0
200	Patients phenotypes and cardiovascular risk in type 2 diabetes: the Jackson Heart Study. <b>2022</b> , 21,	0
199	Contemporary utilization of GLP1 receptor agonists and SGLT2 inhibitors in patients with diagnosed type 2 diabetes and cardiovascular disease in the United States. <b>2022</b> , 108224	
198	Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.	0
197	Potential role of empagliflozin in myocardial iron repletion following ferric carboxymaltose for heart failure. <b>2022</b> ,	
196	Diabetes and Progression of Heart Failure. <b>2022</b> , 79, 2285-2293	0
195	Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D.	0
194	Sodium Glucose Cotransporter-2 Inhibitor Protects Against Diabetic Neuropathy and Nephropathy in Modestly Controlled Type 2 Diabetes: Follow-Up Study. 13,	
193	Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced.	2
192	Synchronous Health Care Delivery for the Optimization of Cardiovascular and Renal Care in Patients with Type 2 Diabetes.	
191	Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time. <b>2022</b> , 23, 6648	1
190	Prevention of Cardiorenal Complications with Sodium-Glucose Cotransporter Type 2 Inhibitors: A Narrative Review.	0
189	GLP-1 Receptor Agonists. <b>2022</b> , 130-160	
188	Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. <b>2022</b> , 37, 415-429	0
187	SGLT2i After Kidney Transplantation: Ready for Prime Time?. Publish Ahead of Print,	0
186	The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes. 1-13	1
185	Diabetes mellitus 2022 Was ist neu?.	
184	A Systematic Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Sympathetic Nervous System Inhibition: An Underrated Mechanism of Cardiorenal Protection. <b>2022</b> ,	1

183	SGLT2 Inhibitors. <b>2022</b> , 95-129	
182	Positionspapier Herzinsuffizienz und Diabetes.	0
181	Heart Failure Burden in Diabetes: Can Fenofibrate Provide Additional Hope?. <b>2022</b> , 45, 1500-1502	0
180	The use of sodium-glucose cotransporter 2 inhibitor in heart failure: The rise of the Roman Empire!. 34, 347-350	
179	Cardiorenal Interactions: A review. <b>2022</b> ,	0
178	Rhythmologische und metabolische Kontrolle.	
177	Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease. <b>2022</b> , 10, 1661	0
176	Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program. <b>2022</b> , 21,	2
175	Positionspapier Herzinsuffizienz und Diabetes.	
174	Clinical Utility of Cardiovascular Risk Scores for Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1 Receptor Agonist or SGLT2 Inhibitor Therapy.	0
173	Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> ,	16.2
172	Trends in insulin resistance: insights into mechanisms and therapeutic strategy. <b>2022</b> , 7,	10
171	Quality of Care Among Patients with Diabetes and Cerebrovascular Disease. Insights from The Diabetes Collaborative Registry. <b>2022</b> ,	
170	Sodium-glucose cotransporter 2 (SGLT2) inhibitors for the prevention and treatment of diabetic kidney disease: A network meta-analysis of randomized controlled trials. <b>2021</b> , 1, 114-124	
169	Consensus statement on the current pharmacological prevention and management of heart failure. <b>2022</b> , 217, 212-217	1
168	The evolution of pillars of therapy to reduce heart failure risk and slow diabetic kidney disease progression. <b>2022</b> , 19, 100187	
167	Effects of Metabolic Medicine and Metabolic Surgery on Patient-Reported Outcomes Among Patients with Type 2 Diabetes.	
166	Hospital Diabetes Meeting 2022. 193229682211108	

165	Cardiovascular and Renal Outcomes among Patients with Type 2 Diabetes using SGLT2 Inhibitors added to Metformin: A Population-Based Cohort Study from the United Kingdom.	
164	Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction. 8,	3
163	Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial. <b>2022</b> , 21,	
162	Potential molecular mechanism of action of sodium-glucose co-transporter 2 inhibitors in the prevention and management of diabetic retinopathy. 1-12	
161	Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?.	1
160	Temporal trends in atherosclerotic cardiovascular disease risk among U.S. adults. Analysis of the National Health and Nutrition Examination Survey, 1999-2018.	0
159	Fournier's Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy. <b>2022</b> ,	
158	WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. <b>2022</b> ,	8
157	Uso potencial de empagliflozina en la repleción miocárdica de hierro tras carboximaltosa ferrica en pacientes con insuficiencia cardíaca. <b>2022</b> ,	0
156	Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?.	
155	Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes-Post Hoc Analyses From the DECLARE-TIMI 58 Trial.	0
154	Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes.	2
153	Acute myocardial infarction in young adults with chronic kidney disease. Publish Ahead of Print,	
152	Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition. <b>2022</b> , 146, 450-462	1
151	Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study. <b>2022</b> , 21,	0
150	Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes. <b>2022</b> , 21,	
149	Questions and answers on the use of aspirin for primary prevention of cardiovascular disease in diabetes. <b>2022</b> , 191, 110043	
148	Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors. <b>2022</b> , 66, 102272	1



147	Combination therapy with an SGLT -2 inhibitor and finerenone in DKD : Are we there yet?.	0
146	SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review. <b>2022</b> , 18, 62-72	0
145	Chapter 1. Chemical Approaches for Beta-cell Biology. <b>2022</b> , 1-52	0
144	Pharmacogenetics of Cardiovascular Prevention in Diabetes: From Precision Medicine to Identification of Novel Targets. <b>2022</b> , 12, 1402	0
143	Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes. <b>2022</b> , 146, 676-686	1
142	Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure.	0
141	SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. <b>2022</b> , 400, 757-767	25
140	Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure. <b>2022</b> , 21,	0
139	Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).	12
138	Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease.	0
137	Type 2 diabetes and cardiovascular disease: risk reduction and early intervention.	0
136	Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).	16
135	O-GlcNAcylation in Renal (Patho)Physiology. <b>2022</b> , 23, 11260	1
134	(Optimizing Foundational Therapies in Patients With HFrEF. How Do We Translate These Findings Into Clinical Care? Translation of the document prepared by the Czech Society of Cardiology). <b>2022</b> , 64, 441-454	0
133	Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19.	0
132	Integrating hypertension and diabetes management in primary health care settings: HEARTS as a tool. <b>2022</b> , 46, 1	0
131	Effect of Glucose Levels on Cardiovascular Risk. <b>2022</b> , 11, 3034	0
130	Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. <i>annrheumdis-2022-222259</i>	2

129	New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure. 9,	0
128	SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis. 9,	0
127	Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure. Publish Ahead of Print,	0
126	Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials. 9,	3
125	Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease. 1-10	0
124	Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus.	0
123	Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial. 9,	0
122	SGLT2 Inhibitors in Heart Failure. <b>2022</b> , 18, 587-596	1
121	Sodium-glucose cotransporter 2 inhibitors and the risk of pneumonia and septic shock: A systematic review and meta-analysis.	1
120	Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events. <b>2022</b> , 18, 597-607	0
119	SGLT2 Inhibitors in Type 2 Diabetes Mellitus. <b>2022</b> , 18, 551-559	0
118	Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: an updated meta-analysis of randomized controlled trials with external adjudication of events.	0
117	Empagliflozin reduces renal lipotoxicity in experimental Alport syndrome.	0
116	Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: a post hoc analysis of the CAPTURE study.	0
115	The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. <b>2022</b> , 51,	0
114	Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis. <b>2022</b> , 19, 147916412211300	0
113	Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease. <b>2022</b> , 17, e0269414	0
112	Real-world evaluation of glucose-lowering therapies and the use of weight-adjusted variable rate intravenous insulin infusion in the management of hyperglycaemia in patients with acute coronary syndrome (REGULATE-ACS). <b>2022</b> ,	0

111	AWARE. A web application to rapidly assess cardiovascular risk in Type 2 Diabetes Mellitus..	0
110	Ketones: the double-edged sword of SGLT2 inhibitors?.	1
109	Advancing a causal role of type 2 diabetes and its components in developing macro- and microvascular complications via genetic studies.	2
108	The changing trajectory of diabetic kidney disease. Publish Ahead of Print,	0
107	Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: A multicenter, randomized, controlled trial.	0
106	The Cardiovascular Benefits and Infections Risk of SGLT2i versus Metformin in Type 2 Diabetes: A Systemic Review and Meta-Analysis. <b>2022</b> , 12, 979	0
105	Value of SGLT-2 inhibitors in the treatment of chronic kidney disease.	0
104	COOrdinating CaRDiology CliNics RANdomized Trial of Interventions to Improve OutcomEs (COORDINATE)  Diabetes: Rationale and Design. <b>2022</b> ,	1
103	Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies.	0
102	KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <b>2022</b> , 102, S1-S127	8
101	Cardiorenal disease management in type 2 diabetes: An expert consensus. <b>2022</b> , 102661	0
100	Knowledge domain and emerging trends in empagliflozin for heart failure: A bibliometric and visualized analysis. 9,	0
99	Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes. <b>2022</b> , 206, 115304	0
98	Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos. <b>2022</b> , 156, 113882	0
97	Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit. <b>2022</b> , 7, 216-224	0
96	Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. <b>2022</b> ,	1
95	The impact of the COVID-19 pandemic on diabetes services: planning for a global recovery. <b>2022</b> ,	0
94	Sequencing of medical therapy in heart failure with a reduced ejection fraction. heartjnl-2022-321497	0

93	Development and Validation of a Lifetime Risk Model for Kidney Failure and Treatment Benefit in Type 2 Diabetes. C.JN.05020422	0
92	Effects of second-line antihyperglycemic drugs on the risk of chronic kidney disease: applying a target trial approach to a hospital-based cohort of Thai patients with type 2 diabetes. <b>2022</b> , 21,	0
91	Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients. 13,	0
90	Atherosclerotic Cardiovascular Disease or Heart Failure: First Cardiovascular Event in Adults with Prediabetes and Diabetes. <b>2022</b> ,	1
89	Rationale and Design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in Patients with High-Risk Diabetic Cardiomyopathy. <b>2022</b> ,	1
88	Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.	0
87	Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes. <b>2022</b> ,	0
86	GLP1RAs vs SGLT2is were associated with lower risk of major adverse limb events and similar risks of heart failure hospitalisation and stroke?.	0
85	Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the SGLT2 inhibitor ertugliflozin.	0
84	HEARTS como herramienta para integrar el manejo de la hipertensi3n y la diabetes en los entornos de atenci3n primaria de salud. <b>2022</b> , 46, 1	0
83	Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis.	0
82	Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. <b>2022</b> , 18, 40-53	0
81	Refractory arterial hypertension: hyperactivity of the sympathetic nervous system, kidney and approaches to antihypertensive drug therapy. <b>2022</b> , 28, 600-608	0
80	Increasing Societal Benefit From Cardiovascular Drugs. <b>2022</b> , 146, 1627-1635	0
79	Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Diabetes and Chronic Kidney Disease (CKD): A Meta-analysis of Randomized Control Trials. <b>2022</b> ,	0
78	Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors. <b>2022</b> , 1,	0
77	Dietary Changes Leading to Euglycemic Diabetic Ketoacidosis in Sodium-Glucose Cotransporter-2 Inhibitor Users: A Challenge for Primary Care Physicians?. <b>2022</b> , 43, 361-366	0
76	Praliquat Promotes Ischemic Leg Reperfusion on Leptin Receptor-Deficient Mice.	1

75	Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease. <b>2022</b> ,	0
74	Efficiency et précision du contrôle glycémique dans le diabète : symphonie inachevée?. <b>2022</b> ,	0
73	Prevention of cardiorenal damage: importance of albuminuria.	1
72	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes. <b>2023</b> , 46, S158-S190	7
71	Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.	0
70	Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care. <b>2022</b> , 21,	0
69	Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure. <b>9</b> ,	0
68	Renoprotective effect of chronic treatment with sodium-glucose cotransporter 2 inhibitors and its associated factors in Japanese patients with chronic heart failure and diabetes. <b>2022</b> , 43, 101152	0
67	The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?. <b>2022</b> , 24, L10-L19	0
66	Benefits of Intensified Reductions in Blood Glucose and in Blood Pressure for Patients with Type 2 Diabetes. <b>2022</b> , 104160	0
65	Caring for Patients With Diabetes in Stroke Neurology.	0
64	11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes. <b>2023</b> , 46, S191-S202	0
63	The relationship between diabetes, obesity and cardiovascular disease phenotypes: a UK Biobank cohort study.	0
62	Diabetes and Stroke: What Are the Connections?.	0
61	Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms.. <b>2023</b> , 106667	0
60	Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK. <b>2023</b> , 11, e003072	0
59	Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.	0
58	Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. <b>2023</b> , 108389	0

57	Effects of sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients.	1
56	Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. <b>2023</b> , 15,	0
55	Évolution des cibles glycémiqes chez le patient diabétique de type 2 au cours des dernières années. <b>2023</b> ,	0
54	Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong. <b>2023</b> , 6, e2251177	1
53	Combined effects of hypertension, hyperlipidemia, and diabetes mellitus on the presence and severity of carotid atherosclerosis in community-dwelling elders: A community-based study. <b>2023</b> , 86, 220-226	0
52	AWARE. A web application to rapidly assess cardiovascular risk in Type 2 Diabetes Mellitus..	0
51	Metformin and empagliflozin modulate monoamine oxidase-related oxidative stress and improve vascular function in human mammary arteries.	0
50	SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease. <b>2023</b> , 11, 279	0
49	Impact of baseline kidney function on the effects of SGLT2 inhibitors on kidney and heart failure outcomes: a systematic review and meta-analysis of randomized controlled trials.	0
48	Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes: a population-based cohort study. <b>2023</b> , 100692	0
47	Effects of ertugliflozin on kidney outcomes in patients with heart failure at baseline in the VERTIS CV trial. <b>2023</b> ,	0
46	Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis. <b>2023</b> , 22,	0
45	Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. <b>2023</b> , 11, 233-241	0
44	The growing clinical effect of SGLT2 inhibitors. <b>2023</b> , 11, 218-219	0
43	Peripheral arterial disease (PAD) is a challenging manifestation of atherosclerosis. <b>2023</b> , 171, 107489	0
42	Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes. <b>2023</b> , 52, 355-375	0
41	Adjusting the Use of Glucose-Lowering Agents in the Real-World Clinical Management of People with Type 2 Diabetes: A Narrative Review.	0
40	Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. <b>2023</b> , 25, 1413-1418	0

- 39 Continuity of Medication Use by US Adults With Diabetes, 2005-2019. **2023**, 6, e2253562 ○
- 38 Diabetic Kidney Disease in Post-Transplant Diabetes Mellitus: Causes, Treatment and Outcomes. **2023**, 11, 470 ○
- 37 Updates in Cardiovascular Disease Prevention, Diagnosis, and Treatment in Women. **2023**, 107, 285-298 ○
- 36 Interest and place of new therapeutic classes in the treatment of elderly diabetic patients. **2023**, 49, 101431 ○
- 35 Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. ○
- 34 The importance of targeting multiple risk markers in patients with type 2 diabetes: A post-hoc study from the CANVAS programme. ○
- 33 Emerging Role of Sodium Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease. Volume 16, 43-57 ○
- 32 RE: Time-dependent Bias Existing in Their Statistical Analysis Must Be Properly Controlled/Avoided Before Drawing Any Conclusions. **2023**, 107, e78-e79 ○
- 31 RE: The Efficacy and Safety of SGLT2 Inhibitor in Kidney Transplant Recipients With Diabetes. **2023**, 107, e80-e81 ○
- 30 New international recommendations for type 2 diabetes [consequences for treatment practice in Norway?]. **2023**, ○
- 29 New diabetes drugs [beneficial for many, harmful for some. **2023**, ○
- 28 SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes. **2023**, 21, ○
- 27 Effects of dietary sodium and protein intake on glomerular filtration rate in subjects with type 2 diabetes treated with sodium glucose cotransporter 2 inhibitors. ○
- 26 Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. 1
- 25 Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes. ○
- 24 Time-Varying Cardiovascular Outcomes of Sodium-Glucose Cotransporter Inhibitors in Patients With Type 2 Diabetes: A Post Hoc Analysis of Pivotal Trials Using Restricted Mean Survival Time. **2023**, 16, ○
- 23 Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes. **2023**, 329, 1261 ○
- 22 Indikationen von Antidiabetika jenseits der Glukosekontrolle. **2023**, 165, 42-49 ○

- 21 Prognostic models for heart failure in patients with type 2 diabetes: a systematic review and meta-analysis. *heartjnl-2022-322044* ○
- 20 Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis. ○
- 19 Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials. **2023**, 198, 110621 ○
- 18 Association of Major Adverse Cardiac Events and Beta-Blockers in Patients with and without Atherosclerotic Cardiovascular Disease: Long-Term Follow-Up Results of the T-SPARCLE and T-PPARCLE Registry in Taiwan. **2023**, 12, 2162 ○
- 17 Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy. **2023**, 11, 58 ○
- 16 Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL , a randomized trial. ○
- 15 SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. 5, ○
- 14 SGLT2 inhibitors breathe life into kidney-disease care. **2023**, 615, S2-S4 ○
- 13 Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease. **2023**, 32, 291-299 ○
- 12 The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in The Netherlands. **2023**, 26, 547-553 ○
- 11 Diabetes: evolution of multifactorial vascular risk reduction. **2023**, 311-335 ○
- 10 Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection. **2023**, 337-363 ○
- 9 Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States. **2023**, ○
- 8 Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). **2023**, 22, ○
- 7 Albuminuria and cardiorenal risk. Publish Ahead of Print, ○
- 6 Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study. Publish Ahead of Print, ○
- 5 Role of the Microbiome in Gut-Heart-Kidney Cross Talk. **2023**, 132, 1064-1083 ○
- 4 The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis. ○



- 3 Management of Heart Failure in Patients With Diabetes Mellitus in the UAE: A Call to Action. **2023**, 28, 107424842311622 ○
- 2 Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors. ○
- 1 Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. ○